跳至主要内容
临床试验/NCT04088851
NCT04088851进行中(未招募)不适用

"Non-invasive Measurement of Hepatic Substrate Flux Rates in People with Diabetes Mellitus Type 2"

German Diabetes Center1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2019年9月11日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
23
试验地点
1
主要终点
Hepatic gluconeogenic flux (U-13C-lactate tracer) (mg/min)

研究概览

简要总结

Investigation of the effects of redox shuttle inhibition by metformin on gluconeogenic flux rates of lactate and glycerol in humans with type 2 diabetes

详细描述

Type 2 diabetes (T2D) is characterized by insulin resistance and relative insulin deficiency leading to hyperglycemia. Enhanced endogenous glucose production during fasting is a key feature of hepatic insulin resistance and a major contributor to deterioration of glycemia. Metformin reduces fasting gluconeogenesis (GNG); the underlying mechanisms are still not fully understood, but involve the inhibition of complexes of the electron transport chain and thus the redox shuttle.

The investigators have previously provided evidence for abnormal hepatic ATP synthesis and mitochondrial efficiency in T2D, but it remains unknown, how and which substrate fluxes account for excessive GNG in T2D. For this reason, this proposal aims at investigating hepatic glucose and energy fluxes in T2D with focus on gluconeogenic contribution of lactate and glycerol to hepatic mitochondrial substrate flux, mitochondrial ATP synthase flux and the activity of the redox shuttle, also after metformin intake, by using a novel combination of positional isotopomer nuclear magnetic resonance (NMR) analysis (PINTA) with multinuclei magnetic resonance spectroscopy (MRS).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None (Participant, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

No Metformin - T2D

Placebo Comparator

Participants with type-2 diabetes will pause metformin 1 g daily for 2 weeks

干预措施: Off Metformin (Drug)

Metformin - T2D

Experimental

Participants with type-2 diabetes will intake metformin 1 g daily for 2 weeks

干预措施: On Metformin (Drug)

结局指标

主要结局

Hepatic gluconeogenic flux (U-13C-lactate tracer) (mg/min)

时间窗: 2 weeks

Hepatic gluconeogenic flux rates from lactate \[mg/min\] in humans with T2D w/wo metformin treatment will be measured by specific tracer metabolism and turnover of the substrates.

Hepatic gluconeogenic flux (glycerol tracer) (mg/min)

时间窗: 2 weeks

Hepatic gluconeogenic flux rates from glycerol \[mg/min\] in humans with T2D w/wo metformin treatment will be measured by specific tracer metabolism and turnover of the substrates.

次要结局

  • Hepatic mitochondrial oxidative flux (mg/min)(2 weeks)
  • Hepatic gammaATP (mmol/L)(2 weeks)
  • Endogenous glucose production (mg/min/kg BW)(2 weeks)
  • Hepatic lipid content (%)(2 weeks)

研究者

发起方
German Diabetes Center
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

"Hepatic Substrate Flux Rates in Type 2 Diabetes" | 临床试验